Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
AcelRx Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. AcelRx Pharmaceuticals shares (ACRX) are listed on the NASDAQ and all prices are listed in US Dollars. AcelRx Pharmaceuticals employs 54 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.96|
|52-week range||$0.97 - $2.94|
|50-day moving average||$1.04|
|200-day moving average||$1.23|
|Wall St. target price||$6.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.36|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||N/A|
|1 month (2021-09-18)||N/A|
|3 months (2021-07-22)||-24.41%|
|6 months (2021-04-22)||-20.66%|
|1 year (2020-10-22)||-48.11%|
|2 years (2019-10-22)||-56.16%|
|3 years (2018-10-22)||3.75|
|5 years (2016-10-21)||3.2|
|Revenue TTM||$3.1 million|
|Gross profit TTM||$-4,633,000|
|Return on assets TTM||-30.31%|
|Return on equity TTM||0%|
|Market capitalisation||$121.6 million|
TTM: trailing 12 months
There are currently 4.9 million AcelRx Pharmaceuticals shares held short by investors – that's known as AcelRx Pharmaceuticals's "short interest". This figure is 16.6% down from 5.9 million last month.
There are a few different ways that this level of interest in shorting AcelRx Pharmaceuticals shares can be evaluated.
AcelRx Pharmaceuticals's "short interest ratio" (SIR) is the quantity of AcelRx Pharmaceuticals shares currently shorted divided by the average quantity of AcelRx Pharmaceuticals shares traded daily (recently around 676041.4266118). AcelRx Pharmaceuticals's SIR currently stands at 7.29. In other words for every 100,000 AcelRx Pharmaceuticals shares traded daily on the market, roughly 7290 shares are currently held short.
However AcelRx Pharmaceuticals's short interest can also be evaluated against the total number of AcelRx Pharmaceuticals shares, or, against the total number of tradable AcelRx Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AcelRx Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AcelRx Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0422% of the tradable shares (for every 100,000 tradable AcelRx Pharmaceuticals shares, roughly 42 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against AcelRx Pharmaceuticals.
Find out more about how you can short AcelRx Pharmaceuticals stock.
We're not expecting AcelRx Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, AcelRx Pharmaceuticals's shares have ranged in value from as little as $0.97 up to $2.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AcelRx Pharmaceuticals's is 0.8772. This would suggest that AcelRx Pharmaceuticals's shares are less volatile than average (for this exchange).
AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.